Vanguard Global Advisers
IMUX icon

Vanguard Global Advisers’s Immunic IMUX Stock Holding History

Vanguard Global Advisers’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Sell
3,186
-1
-0% -$12 ﹤0.01% 3075
2026
Q1 		$35.4K Buy
+3,187
New +$28.5K ﹤0.01% 3151

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Global Advisers's IMUX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Immunic (IMUX) stake by 0.03% in Q2 2026, selling an estimated $12 and leaving 3,186 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #3075.

Vanguard Global Advisers first reported a position in IMUX in Q1 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Vanguard Global Advisers held 3,186 shares of Immunic worth $49K as of Q2 2026.
  • Vanguard Global Advisers sold 1 Immunic share in Q2 2026, an estimated $12.
  • Immunic made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3075 holding.
  • Vanguard Global Advisers first reported a position in Immunic in Q1 2026 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.